| Manu | Date: Tuesday, 28-May-2019, 7:57 PM | Message # 1 |
--dragon lord--
Group: undead
Messages: 13976
Status: Offline
| Human lifespan could soon pass 100 years thanks to medical tech, says BofA
Thomas Franck
@TOMWFRANCK
One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to Bank of America analysts.
The analysts say companies such as Illumina and Alphabet are on the cusp of "bringing unprecedented increases to the quality and length of human lifespans."
The Bank of America team highlights five key sub-themes, as well as several stocks with exposure to the trend.
One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to one of Wall Street’s major investment banks.
Bank of America Merrill Lynch analysts Felix Tran and Haim Israel believe that genome sequencers such as Illumina, high-tech players such as Alphabet and biotech companies such as Novartis are on the cusp of “bringing unprecedented increases to the quality and length of human lifespans.”
Innovation in genome science, big data and “ammortality,” which includes wearable technology and products in the so-called wellness space, could soon prolong healthy human life well beyond 100 years, BofA told clients Wednesday.
“Medical knowledge will double every 73 days by 2020 vs. every 3.5 (years) in 2010, and genomic sequencing costs have fallen 99.999% since 2003,” Israel and Tran wrote. “This has enabled a new frontier in precision medicine to further extend life expectancy, heralding a ‘techmanity’ (technology meets humanity) revolution.”
Extending human life to new bounds — long the domain of science fiction novels — could increasingly be a compelling way to make money in the public markets. With a market size already at $110 billion, the Bank of America team highlighted five key sub-themes — genomics, big data/AI health, future food, “ammortality” and “moonshot medicine” — as well as several stocks that offer exposure to the trend.
Read more/ full article/source - https://www.cnbc.com/2019....th.html
|
| |
| |
